INO Inovio Pharmaceuticals, Inc.
Latest News

$0.37-0.0071 (-1.87%)3:59 PM 10/04/23

NASDAQ | $USD | Post-Market: $0.38 +0.01 (+2.53%) 4:20 PM

News

Show Full Stories

This feature available only for pro users

Type:

Date Range:

Inovio gains FDA breakthrough status for DNA therapy

Inovio Pharmaceuticals GAAP EPS of -$0.13 beats by $0.01, revenue of $0.23M misses by $0.03M

Inovio Pharmaceuticals Q2 2023 Earnings Preview

Inovalis Real Estate Investment Trust FFO of C$0.22

Inovio to shed 30% of staff in restructuring drive

Russell 3000 rejig: InMode, Assertio among healthcare additions; Inovio, Bionano among deletions

SNDL, Invitae among additions to Russell microcap; Inovio, Bionano among deletions

Inovio wins orphan drug status for HPV-related candidate in Europe

Inovio Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $0.11M misses by $0.17M

Inovio Pharmaceuticals Q1 2023 Earnings Preview

Inovio's respiratory disorder therapy on way to get orphan drug status in EU

Inovio gains on Phase 1 data for Ebola booster shot

Inovio stock rises amid mixed trial results for cervical lesions drug; Q4 clinical updates

Inovio Pharmaceuticals GAAP EPS of -$1.17 misses by $0.06, revenue of $10.26M misses by $0.29M

Inovio Pharmaceuticals FY 2022 Earnings Preview

Inovio in strategic reorganization; 11% headcount reduction

Inovio ends development of candidates for Lassa fever and Middle East Respiratory Syndrome

Inovio Pharmaceuticals stock rises on Q3 profit beat, raised cash runway guidance

Inovio Pharmaceuticals GAAP EPS of -$0.15 beats by $0.15, revenue of $9.15M

Inovio Pharmaceuticals Q3 2022 Earnings Preview

Amazon.com, Pinduoduo, JD.com among premarket losers' pack

Inovio Pharmaceuticals stops development of COVID-19 booster shot candidate

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Moderna, Novavax hit 52-week lows

Inovio beats on the top line but misses on the bottom; quarterly net loss widens 32%

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Inovio Pharmaceuticals Q2 2022 Earnings Preview

Inovio Pharmaceuticals slotted at Sector Perform by RBC Capital in initial rating look

Inovio to cut workforce by 18% as part of corporate reorganization

INOVIO appoints Dr. Michael Sumner as CMO

Inovio Pharma, Bionano Genomics among health care stocks to join Russell Microcap Index; Tonix Pharma, iBio to leave

Inovio announces positive survival results from trial testing glioblastoma treatment

Inovio downgraded at Oppenheimer as CEO departure adds uncertainty

Inovio Pharmaceuticals falls 20% on Q1 misses, announcement of new CEO

Jacqueline Shea named new CEO of Inovio

Inovio Pharmaceuticals Non-GAAP EPS of -$0.36, revenue of $0.2M

Inovio Pharmaceuticals Q1 2022 Earnings Preview

Global group calls for $15 billion this year for long term COVID response

Inovio COVID vaccine weaker vs Omicron in lab test; phase 3 trial enrollment paused

Inovio Pharmaceuticals results miss on the bottom line; shares down 9%

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.